- Page 2 and 3:
GLOBALTUBERCULOSISREPORT2012
- Page 4 and 5:
ContentsAbbreviationsivAcknowledgem
- Page 6 and 7:
AcknowledgementsThis report on glob
- Page 8 and 9:
WHO Western Pacific RegionShalala A
- Page 10 and 11:
Executive SummaryThe World Health O
- Page 12 and 13:
CHAPTER 1IntroductionBOX 1.1Basic f
- Page 14 and 15:
TABLE 1.1 Targets for the scale-up
- Page 16 and 17:
TABLE 1.2 Reporting of data in the
- Page 18 and 19:
BOX 2.1Uncertainty in estimates of
- Page 20 and 21:
TABLE 2.2 Estimated burden of disea
- Page 22 and 23:
FIGURE 2.5 Estimated TB incidence r
- Page 24 and 25:
FIGURE B2.2.1Reporting of notificat
- Page 26 and 27:
FIGURE 2.8Estimated TB incidence ra
- Page 28 and 29:
FIGURE 2.11 Countries (in blue) for
- Page 30 and 31:
FIGURE 2.12 Trends in estimated TB
- Page 32 and 33:
● producing and widely disseminat
- Page 34 and 35:
FIGURE 2.16 Progress in global cove
- Page 36 and 37:
BOX 2.6Efforts by the Task Force to
- Page 38 and 39:
CHAPTER 3TB case notificationsand t
- Page 40 and 41:
BOX 3.1 1Definitions of TB casesDef
- Page 42 and 43:
TABLE 3.3 Contribution of public-pr
- Page 44 and 45:
BOX 3.4Integrating community-based
- Page 46 and 47:
TABLE 3.4 Estimates of the case det
- Page 48 and 49: TABLE 3.5 Treatment success for new
- Page 50 and 51: CHAPTER 4Drug-resistant TBKEY FACTS
- Page 52 and 53: FIGURE 4.2 Percentage of new TB cas
- Page 54 and 55: BOX 4.1Frequencies of resistance to
- Page 56 and 57: FIGURE 4.6 Number of MDR-TB cases e
- Page 58 and 59: FIGURE 4.7Notified cases of MDR-TB
- Page 60 and 61: egimens globally, providing more su
- Page 62 and 63: 5.1 Funding for TB care and control
- Page 64 and 65: TABLE 5.2 NTP budgets, available fu
- Page 66 and 67: FIGURE 5.5Trends in domestic and do
- Page 68 and 69: FIGURE 5.6Domestic funding as a per
- Page 70 and 71: FIGURE 5.8Cost per TB patient succe
- Page 72 and 73: FIGURE 5.10 Total cost and unit cos
- Page 74 and 75: ● The 14 countries not included i
- Page 76 and 77: on public health by an external Exp
- Page 78 and 79: evised as a result of the introduct
- Page 80 and 81: TABLE 6.2 Incorporation of WHO poli
- Page 82 and 83: FIGURE 6.3The Supranational Referen
- Page 84 and 85: of TB disease by 65%, irrespective
- Page 86 and 87: FIGURE 7.3Percentage of TB patients
- Page 88 and 89: BOX 7.1Accelerating progress in pro
- Page 90 and 91: TABLE 7.2 Assumptions used to estim
- Page 92 and 93: FIGURE 8.1 The development pipeline
- Page 94 and 95: sputum specimens and TB isolates fr
- Page 96 and 97: cal trial sites and building labora
- Page 98: new TB vaccine candidate. A Phase I
- Page 103 and 104: incidence. In some countries, howev
- Page 105 and 106: For consistency with VR- or survey-
- Page 107 and 108: TABLE A1.2POSSIBLE CATEGORIES OF IN
- Page 109 and 110: spline interpolation. If only one p
- Page 111 and 112: 7. Projections of incidence, preval
- Page 114: ANNEX 2Country profiles
- Page 117 and 118: BANGLADESHPopulation 2011 150 milli
- Page 119 and 120: CAMBODIAPopulation 2011 14 millionH
- Page 121 and 122: DEMOCRATIC REPUBLIC OF THE CONGOPop
- Page 123 and 124: INDIAPopulation 2011 1 241 millionH
- Page 125 and 126: KENYAPopulation 2011 42 millionHIGH
- Page 127 and 128: MYANMARPopulation 2011 48 millionHI
- Page 129 and 130: PAKISTANPopulation 2011 177 million
- Page 131 and 132: RUSSIAN FEDERATIONPopulation 2011 1
- Page 133 and 134: THAILANDPopulation 2011 70 millionH
- Page 135 and 136: UNITED REPUBLIC OF TANZANIAPopulati
- Page 137 and 138: ZIMBABWEPopulation 2011 13 millionH
- Page 140 and 141: WHO AFRICAN REGIONPopulation 2011 8
- Page 142 and 143: WHO EASTERN MEDITERRANEAN REGIONPop
- Page 144 and 145: WHO SOUTH-EAST ASIA REGIONPopulatio
- Page 146: ANNEX 4Global, regionaland country-
- Page 149 and 150:
Estimates of mortality, prevalence
- Page 151 and 152:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 153 and 154:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 155 and 156:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
- Page 157 and 158:
Estimates of mortality, prevalence
- Page 159 and 160:
YEARPOPULATION(MILLIONS)MORTALITY (
- Page 161 and 162:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 163 and 164:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 165 and 166:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 167 and 168:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 169 and 170:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 171 and 172:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 173 and 174:
-% OF TB PATIENTS WITHKNOWN HIV STA
- Page 175 and 176:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
- Page 177 and 178:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
- Page 179 and 180:
SMEAR LABS % OF SMEARPER 100K LABS
- Page 181 and 182:
Estimates of mortality, prevalence
- Page 183 and 184:
YEARPOPULATION(MILLIONS)MORTALITY (
- Page 185 and 186:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 187 and 188:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 189 and 190:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 191 and 192:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 193 and 194:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 195 and 196:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 197 and 198:
-% OF TB PATIENTS WITHKNOWN HIV STA
- Page 199 and 200:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
- Page 201 and 202:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
- Page 203 and 204:
SMEAR LABS % OF SMEARPER 100K LABS
- Page 205 and 206:
Estimates of mortality, prevalence
- Page 207 and 208:
YEARPOPULATION(MILLIONS)MORTALITY (
- Page 209 and 210:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 211 and 212:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 213 and 214:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 215 and 216:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 217 and 218:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
- Page 219 and 220:
SMEAR LABS % OF SMEARPER 100K LABS
- Page 221 and 222:
Estimates of mortality, prevalence
- Page 223 and 224:
YEARPOPULATION(MILLIONS)MORTALITY (
- Page 225 and 226:
YEARPOPULATION(MILLIONS)MORTALITY (
- Page 227 and 228:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 229 and 230:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 231 and 232:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 233 and 234:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 235 and 236:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 237 and 238:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 239 and 240:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 241 and 242:
-% OF TB PATIENTS WITHKNOWN HIV STA
- Page 243 and 244:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
- Page 245 and 246:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
- Page 247 and 248:
SMEAR LABS % OF SMEARPER 100K LABS
- Page 249 and 250:
Estimates of mortality, prevalence
- Page 251 and 252:
YEARPOPULATION(MILLIONS)INCIDENCE (
- Page 253 and 254:
TREATMENT SUCCESS (%) a1995-2010YEA
- Page 255 and 256:
-% OF TB PATIENTS WITHKNOWN HIV STA
- Page 257 and 258:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
- Page 260 and 261:
WESTERN PACIFIC REGIONTable A4.1 Es
- Page 262 and 263:
MORTALITY (EXCLUDING HIV) PREVALENC
- Page 264 and 265:
YEARPOPULATION(MILLIONS)MORTALITY (
- Page 266 and 267:
INCIDENCE (INCLUDING HIV) INCIDENCE
- Page 268 and 269:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 270 and 271:
NEW AND RELAPSENOTIFICATION RATE a1
- Page 272 and 273:
% OF COHORTTREATMENT SUCCESS (%) a1
- Page 274 and 275:
% OF COHORTTREATMENT SUCCESS (%) a1
- Page 276 and 277:
-% OF TB PATIENTS WITHKNOWN HIV STA
- Page 278 and 279:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
- Page 280 and 281:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
- Page 282:
The World Health Organization monit